News
Pennington Biomedical researchers and their collaborators observed decreased activity in the brain regions responsible for ...
2d
The Brighterside of News on MSNWeight-loss drug Tirzepatide significantly slows breast cancer growth, study findsKey Takeaways ・The weight-loss drug tirzepatide reduced both body fat and tumor growth in obese mice with breast cancer.
Preclinical study shows oral PL7737 agonist outperforms tirzepatide alone in rodent models, supporting Palatin’s plans for ...
For adults with obesity treated with once-weekly tirzepatide, cardiometabolic risk factor improvements were positively ...
New data and analyses presented at the American Diabetes Association’s annual meeting highlight the priorities for the next ...
Hengrui has reported topline data from the 301 study of their dual GLP-1 and GIP agonist HRS9531, administered as a ...
Wegovy, India’s first injectable semaglutide for chronic weight management, recorded Rs 2.54 crore in sales in June ...
2d
Vietnam Investment Review on MSNAscletis Completes Dosing in US Obesity Drug Combo TrialCombining ASC47 with semaglutide, the new therapy aims to reshape obesity treatment with targeted, once-monthly injections.
MariTide helped participants lose up to 20% of their body weight in a year-long trial. But it could be years before the new ...
Popular weight loss medications like Ozempic can help reverse low testosterone levels in men with obesity or Type 2 diabetes, ...
Researchers conducted a post hoc analysis of the SURMOUNT-1 trial to assess the effect of tirzepatide on kidney function in prediabetes with obesity or overweight.
Researchers found that tirzepatide, a medication primarily used for treating type 2 diabetes and weight loss, reduced body ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results